In the Claims

Please amend the claims follows:

37. (Five times amended) A polypeptide having only a partial sequence from short consensus repeat 3 of complement receptor 1, wherein the polypeptide comprises a 6 to 23 amino acid portion of SEQ ID NO: 1, and wherein the polypeptide has at least one amino acid sequence selected from the group consisting of:

(a) amino acids 6-11 OF SEQ ID NO: 1, and

(b) amino acids 11-20 of SEQ ID NO: 1.

38. (Three times amended) The polypeptide according to claim 37, further comprising a cysteine residue at the carboxyl terminus and the amino terminus of the polypeptide, thereby providing a capability to form a cyclic polypeptide via formation of a disulfide bond.

39. (Four times amended) The polypeptide according to claim 37, further comprising a amino acid residue located at least one position selected from the group consisting of the carboxyl terminus and the amino terminus of the polypeptide, wherein the amino acid residue with a chemically reactive side chain is selected from the group

consisting of cysteine, lysine, glutamic acid, arginine, asparagine, glutamine, tryptophan, serine, threonine and aspartic acid.

40. (Three times amended) The polypeptide according to claim 39, wherein the amino acid residue with a chemically reactive side chain is derivatized or derivatizable.

41. (Three times amended) The polypeptide according to claim 40, wherein the terminal amino acid residue is cysteine derivatized with S-(2-pyridyl) dithio.

42. (Three times amended) The polypeptide according to claim 37, wherein the polypeptide is altered to remove amino acid residues with chemically reactive side chains.

43. (Five times amended) A multimeric polypeptide having only a partial sequence from short consensus repeat 3 of complement receptor 1, wherein the polypeptide comprises at least two polypeptide constituents that comprise a 6 to 23 amino acid portion of SEQ ID NO: 1, and wherein the polypeptide constituents have at least one amino acid sequence selected from the group consisting of:

(a) amino acids 6-11 OF SEQ ID NO: 1, and

(b) amino acids 11-20 of SEQ ID NO: 1 , wherein the polypeptide constituents do not comprise a mature short consensus repeat-3 and the polypeptide constituents are linked to a core structure.

44. (Three times amended) The multimeric polypeptide according to claim 43, wherein the core structure comprises a derivative of lysine.

45. (Twice amended) The multimeric polypeptide according to claim 43, wherein the core structure is $(lys)_4(lys)_2$ lys ala or Tris (aminoethyl) amine and 1,2,4,5 benzene tetracarboxylic acid.

46. (Twice Amended) The multimeric polypeptide according to claim 43, wherein the multimeric polypeptide comprises two to eight polypeptides having only a partial sequence from short consensus repeat 3 of complement receptor 1.

47. (Twice amended) The multimeric polypeptide according to claim 43, which comprises $(Lys)_4$ $(Lys)_2$ Ala-OH) linked through N-(ϵ-thiopropionyl) linkers that are disulfide bonded to cysteine thiol of the polypeptide SGGRKVFELVGEPSIYC.

48. (Five times amended) A chimeric polypeptide comprising a host protein and as an insert a polypeptide having only a partial sequence from short consensus

repeat 3 of complement receptor 1, wherein the polypeptide having only a partial sequence from short consensus repeat 3 of complement receptor 1 comprises a 6 to 23 amino acid portion of SEQ ID NO: 1, wherein the polypeptide having only a partial sequence from short consensus repeat 3 of complement receptor 1 has at least one amino acid sequence selected from the group consisting of:

I9

(a) amino acids 6-11 of SEQ ID NO: 1, and

(b) amino acids 11-20 of SEQ ID NO: 1,

wherein the polypeptide having only a partial sequence from short consensus repeat 3 of complement receptor 1 is inserted into a non-essential region of the host protein.

I10

49. (Amended) The chimeric polypeptide according to claim 48, wherein the host protein contains at least one short consensus repeat of complement receptor 1.

I11

51. (Three times amended) The polypeptide according to claim 37, wherein the polypeptide is selected from the group consisting of:

linear CNPGSGGRKVFELVGEPSIYC (SEQ ID NO: 4);

cyclic CNPGSGGRKVFELVGEPSIYC (SEQ ID NO: 4);

SGGRKVFELVGEPSIYC (SEQ ID NO: 5);

CGGRKVFC (SEQ ID NO: 7); and

FELVGEPSIYSTSNDDQVGIWSG (SEQ ID NO: 8).

52. (Five times amended) A process for preparing a polypeptide having only a partial sequence from short consensus repeat 3 of complement receptor 1, wherein the polypeptide comprises a 6 to 23 amino acid portion of SEQ ID NO: 1, and wherein the polypeptide has at least one amino acid sequence selected from the group consisting of:

(a) amino acids 6-11 of SEQ ID NO: 1, and

(b) amino acids 11-20 of SEQ ID NO: 1, comprising the step of:

condensing peptide units. Lacks full positive recognition of step.

53. (Five times amended) A process for preparing a polypeptide having only a partial sequence from short consensus repeat 3 of complement receptor 1 , wherein the polypeptide comprises a 6 to 23 amino acid portion of SEQ ID NO: 1, and wherein the polypeptide has at least one amino acid sequence selected from the group consisting of:

(a) amino acids 6-11 of SEQ ID NO: 1, and

(b) amino acids 11-20 of SEQ ID NO: 1, comprising the step of:

expressing DNA encoding the polypeptide in a recombinant host cell, and recovering the polypeptide.

54. (Five times amended) An isolated polynucleotide encoding a polypeptide having only a partial sequence from short consensus repeat 3 of complement receptor 1 , wherein the polypeptide comprises a 6 to 23 amino acid portion of SEQ ID NO: 1, and wherein the polypeptide has at least one amino acid sequence selected from the group consisting of:

I12

(a) amino acids 6-11 of SEQ ID NO: 1, and

(b) amino acids 11-20 of SEQ ID NO: 1.

57. (Five times amended) A pharmaceutical composition comprising

(1) a therapeutically effective amount of a polypeptide having only a partial sequence from short consensus repeat 3 of complement receptor 1 , wherein the polypeptide comprises a 6 to 23 amino acid portion of SEQ ID NO: 1, and wherein the polypeptide has at least one amino acid sequence selected from the group consisting of:

I13

(a) amino acids 6-11 of SEQ ID NO: 1, and

(b) amino acids 11-20 of SEQ ID NO: 1, and

(2) a pharmaceutically acceptable carrier or excipient.